№ lp_1_2_69485
File format: docx
Character count: 7296
File size: 37 KB
The document outlines the terms and conditions for entities applying for admission to the official list of ASX and the quotation of their securities, detailing warranties, compliance with ASX listing rules, and required documentation.
Year:
1996
Region / City:
Australia
Subject:
ASX Listing Application
Document Type:
Agreement
Organ / Institution:
ASX Limited
Author:
ASX
Target Audience:
Entities seeking admission to the official list of ASX
Period of Validity:
From 01/07/96
Approval Date:
01/07/96
Amendment Dates:
01/07/97, 01/07/98, 01/09/99, 13/03/00, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 20/07/07, 01/01/12, 01/05/13, 02/11/15, 19/12/16
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
Sydney
Topic:
Conformance Testing, ASX, FIX Protocol
Document Type:
Checklist
Organization:
ASX Limited
Author:
ASX Operations
Target Audience:
Customers performing ASX conformance tests
Validity Period:
Until the test completion
Approval Date:
January 2026
Revision Date:
N/A
Year:
2021
Region/City:
Australia
Topic:
Conformance Testing, ASX
Document Type:
Checklist
Organ/Institution:
ASX
Author:
ASX
Target Audience:
Trading Participants, Software Vendors
Effective Period:
August 2021
Approval Date:
August 2021
Modification Date:
Not specified
Year:
2023
Note:
Region / City
Subject:
Application Conformance Test
Document Type:
Checklist
Organization / Institution:
ASX
Context:
Pre-test checklist for ASX TradeITCH and OUCH application conformance, providing guidelines for participants to confirm their application details and testing procedures.
Year:
2022
Region / city:
Australia
Theme:
Application Conformance Test
Document type:
Checklist
Organ / institution:
ASX
Author:
ASX
Target audience:
Customers involved in conformance testing
Period of validity:
Not specified
Approval date:
May 2022
Date of changes:
May 2022
Year:
2025
Region / City:
Australia
Topic:
TradeFIX Conformance Testing
Document Type:
Checklist
Organization / Institution:
ASX
Author:
ASX
Target Audience:
Participants and Vendors involved in ASX testing
Effective Period:
February 2025
Approval Date:
Not specified
Date of Changes:
Not specified
Version:
1.4
Date:
July 2023
Application:
ASX 24 Conformance Test Checklist
Note:
Test Contact Name
Test Type:
Conformance Test
Test Script:
Mandatory (M) / Optional (O)
Test Process Duration:
10 continuous business days
Test Modifications:
Not Supported (NS)
Test Attestation:
Customer responsibility
1.2:
July 2016
1.3:
August 2017
1.4:
July 2023
Disclaimer:
General information, subject to change, no liability from ASX
Year:
2019
Region / City:
Australia
Subject:
ASX Listing Rules, Corporate Governance
Document Type:
Checklist
Entity / Organization:
ASX (Australian Securities Exchange)
Author:
ASX Listings Department
Target Audience:
Entities applying for ASX Listing or listed entities
Period of Validity:
Ongoing
Approval Date:
1 December 2019
Amendment Date:
N/A
Note:
Year
Subject:
Gender equity, ASX 300 boards
Document Type:
Podcast Transcript
Organization / Institution:
University of Alberta, UTS
Author:
Deb Verhoeven
Target Audience:
Academics, board members, researchers, general public interested in gender equity
Organization:
National Steel and Shipbuilding Company
Program:
AS(X) Preliminary Design Program
Prime Contract Number:
N00024-22-C-2504
Contracting Authority:
Department of the Navy
Command:
Naval Sea Systems Command (NAVSEA)
Document Type:
Prime Contract Clauses and Special Provisions
Security Level:
SECRET/NOFORN
Facility Clearance Requirement:
Active SECRET Facility Clearance (FCL)
Personnel Requirement:
United States citizens with final SECRET clearance
Applicable Regulations:
FAR and DFARS
Referenced Instruction:
SECNAVINST 5510.36
Related Systems:
SIPRNet, STE, DTIC, Defense Courier Service
International Context:
NATO operations compatibility requirement
Subject Matter:
Security, specifications, standards, data access, and contractual compliance
Date:
28 October 2024
Time:
10:00 am AEDT
Company:
ASX Limited
Location:
Online and In-Person AGM
Subject:
2024 Annual General Meeting Transcript
Type of Document:
Official Company Meeting Transcript
Author:
Damian Roche, Chair of ASX
Target Audience:
ASX Shareholders and Stakeholders
Date of Publication:
28 October 2024
Period of Relevance:
2024 Financial Year
Official Website for Access:
ASX Website
End of Meeting:
11:30 am AEDT
Agency:
United States Securities and Exchange Commission
Form number:
Form 25
Document type:
Regulatory filing form
Jurisdiction:
United States
Legal basis:
Securities Exchange Act of 1934
Applicable rules:
Rule 12d2-2 (17 CFR 240.12d2-2); Rule 19d-1 (17 CFR 240.19d-1)
OMB control number:
3235-0080
OMB expiration date:
March 31, 2021
Filing system:
EDGAR
Effective delisting period:
10 days after filing
Effective withdrawal of registration period:
90 days after filing
Revision identifier:
SEC 1654 (03-06)
Year:
2025
Region / city:
Australia
Subject:
Oncology, Pharmaceutical Submission
Document Type:
Pharmaceutical Benefits Scheme (PBS) Submission
Organ / Institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
JANSSEN-CILAG PTY LTD
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Ongoing
Approval Date:
Pending
Date of modifications:
N/A
Year:
2025
Region / City:
Uganda
Theme:
Procurement, Health Services, Public Contracts
Document Type:
Pre-Qualification Notice
Authority:
Mulago Specialised Women and Neonatal Hospital
Author:
Not specified
Target Audience:
Providers, Contractors, Suppliers
Period of Validity:
2025-2028
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2024
Region / Country:
Australia
Therapeutic Area:
Gastroenterology
Type of Document:
Regulatory submission / PBAC evaluation
Product:
Budesonide 4 mg suppository (Budenofalk®)
Comparator:
Budesonide 2 mg foam (Budenofalk®), prednisolone suppositories and enemas, hydrocortisone acetate enemas
Regulatory Authority:
TGA (Therapeutic Goods Administration)
Intended Use:
Short-term treatment of mild to moderate ulcerative colitis limited to the rectum
Prescriber Type:
Medical practitioners, Nurse practitioners
PBS Benefit Type:
Unrestricted
Maximum Quantity:
1 pack, 30 units
Treatment Duration:
up to 8 weeks per script
Clinical Evidence:
Phase 3, randomized, double-blind, double-dummy, non-inferiority trial (BUS-4/UCA)
Year:
2025
Region / City:
Windhoek
Subject:
Public Administration, Consultancy, Research
Document Type:
Official Announcement
Institution:
Namibia Institute of Public Administration and Management (NIPAM)
Author:
NIPAM
Target Audience:
Facilitators, Researchers, Consultants, Public Sector Experts
Period of Validity:
Until 10 February 2025
Approval Date:
Not specified
Date of Last Modification:
Not specified
Year:
2011
Regulation:
The Companies Regulations 2011, as amended
Region / Market:
Johannesburg Stock Exchange (JSE)
Document Type:
Regulatory guidance / compliance document
Scope:
Pre-Listing Statements (PLS), Revised Listing Particulars (RLP), Circulars
Language:
English
Applicable Parties:
Issuers and applicants seeking listing on JSE
Requirements:
Disclosure obligations, material contracts, corporate actions
Website Obligation:
Operational website for disclosure compliance
Audience:
Investors, shareholders
Year:
[Year]
Region / City:
Wellington
Topic:
Securities listing and quotation
Document Type:
Application
Organization:
NZ RegCo
Author:
[Issuer Name]
Target Audience:
NZX, securities issuers
Effective Period:
[Date]
Approval Date:
[Date]
Amendment Date:
[Date]
Year:
2023
Region / city:
Australia
Topic:
Oncology, Pharmaceuticals
Document Type:
Resubmission
Institution:
Australian Government, Pharmaceutical Benefits Advisory Committee
Author:
AstraZeneca Pty Ltd.
Target Audience:
Healthcare professionals, regulatory bodies
Effective Period:
Ongoing
Approval Date:
November 2021
Date of Changes:
November 2021
Note:
Year